[Dr.Vad]

Неделю назад вышла новая работа о местном применении тимолола: недоношенные дети с низкой массой тела требуют более тщательного наблюдения:

topical timolol appeared to provide safe treatment for IHs in full-term infants receiving a dose of less than 0.2 mg/kg/day, but infants with a PMA of less than 44 weeks and weight at treatment initiation of less than 2,500 g may be at risk of adverse events, including bradycardia, hypotension, apnea, and hypothermia. We recommend close monitoring of temperature, blood pressure, and heart rate in premature and low-birthweight infants with IHs at initiation of and during therapy with topical timolol.
---
Adverse Events in Young and Preterm Infants Receiving Topical Timolol for Infantile Hemangioma. [Ссылки доступны только зарегистрированным пользователям ]